(wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup>, which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R<sup>5</sup> represents a hydrogen atom, a lower alkyl group, or a lower acyl group, x represents a monosaccharic residue or an oligosaccharic residue optionally having the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6).

21. (New) The method of claim 20 wherein said chromanol glycoside is 2-( $\alpha$ -D-glycopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-( $\beta$ -D-galactopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, and 2-( $\alpha$ -D-mannopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol.

## REMARKS

New claims 7-21 have been added. Attached is a clean copy of new claims 7-21. Claims 1-21 are in this application. No new matter has been entered.

Applicants believe that the claims would have been allowable as originally filed. Accordingly, applicants assert that no claims have been narrowed within the meaning of the Federal Circuit's recent decision in *Festo Corp. v. Shoketsu Kinzoku Kohyo Kabushiki Co.*, No. 95-1066, 2000 WL 1753646 (Fed. Cir. Nov. 29, 2000).

A prompt and favorable action on the merits is earnestly solicited. It is believed that no fee is required. The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 13-2165.

Respectfully submitted,

Diane Dunn McKa

Reg. No. 34,586

Attorney for Applicant

DATE: October 26, 2001

MATHEWS, COLLINS, SHEPHERD & GOULD 100 Thanet Circle, Suite 306 Princeton, NJ 08540 (609) 924-8555 - Telephone (609) 924-3036 - Facsimile